Remarkable regression of inoperable pancreatic grade 3 neuroendocrine neoplasm after radioligand therapy with [177Lu]Lu-DOTATATE and [90Y]Y‑DOTATATE

Pol Arch Intern Med. 2023 Nov 29;133(11):16576. doi: 10.20452/pamw.16576. Epub 2023 Oct 2.

Authors

Adam D Durma¹, Marek Saracyn², Maciej Kołodziej², Katarzyna Jóźwik-Plebanek², Grzegorz Kamiński²

Affiliations

¹ Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine – National Research Institute, Warsaw, Poland. adurma@wim.mil.pl
² Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine – National Research Institute, Warsaw, Poland

PMID: 37795839
DOI: 10.20452/pamw.16576

No abstract available

MeSH terms

Humans
Pancreatic Neoplasms* / radiotherapy
Positron-Emission Tomography
Yttrium Radioisotopes*

Substances

copper dotatate CU-64
Yttrium-90
Yttrium Radioisotopes
Lutetium-177